ES2146530B1 - USE OF THE IGF-I GROWTH FACTOR IN THE MANUFACTURE OF USEFUL COMPOSITIONS IN THE TREATMENT OF CEREBELAR ATAXY. - Google Patents
USE OF THE IGF-I GROWTH FACTOR IN THE MANUFACTURE OF USEFUL COMPOSITIONS IN THE TREATMENT OF CEREBELAR ATAXY.Info
- Publication number
- ES2146530B1 ES2146530B1 ES9702702A ES9702702A ES2146530B1 ES 2146530 B1 ES2146530 B1 ES 2146530B1 ES 9702702 A ES9702702 A ES 9702702A ES 9702702 A ES9702702 A ES 9702702A ES 2146530 B1 ES2146530 B1 ES 2146530B1
- Authority
- ES
- Spain
- Prior art keywords
- igf
- manufacture
- treatment
- ataxia
- cerebelar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010003591 Ataxia Diseases 0.000 title abstract 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title abstract 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003102 growth factor Substances 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 101710138657 Neurotoxin Proteins 0.000 abstract 2
- 239000002581 neurotoxin Substances 0.000 abstract 2
- 231100000618 neurotoxin Toxicity 0.000 abstract 2
- 206010008025 Cerebellar ataxia Diseases 0.000 abstract 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 abstract 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 230000001228 trophic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La ataxia cerebelar experimental inducida por la administración de una neurotoxina a ratas macho determina una descoordinación motora de origen neural que impide al animal moverse. Hasta ahora no existe tratamiento y solamente se han conseguido recuperaciones parciales, administrando factores tróficos como CNFF, NGF o FGF-2 directamente en el cerebro lo que hacía inviable su posible aplicación a la ataxia de los seres humanos. La invención describe la utilización de IGF-I en la fabricación de composiciones que por administración periférico vía subcutánea continua, en el modelo de ataxia experimental mencionado, consiguen una curación completa de los animales, evitando que se mueran las neuronas afectadas por la neurotoxina y haciendo que la curación sea definitiva.Experimental cerebellar ataxia induced by the administration of a neurotoxin to male rats determines a motor uncoordination of neural origin that prevents the animal from moving. Until now there is no treatment and only partial recoveries have been achieved, administering trophic factors such as CNFF, NGF or FGF-2 directly in the brain which made its possible application to the ataxia of human beings unfeasible. The invention describes the use of IGF-I in the manufacture of compositions that by continuous peripheral administration via subcutaneous route, in the mentioned experimental ataxia model, achieve a complete cure of the animals, preventing neurons affected by neurotoxin from dying and causing The cure is definitive.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES9702702A ES2146530B1 (en) | 1997-12-26 | 1997-12-26 | USE OF THE IGF-I GROWTH FACTOR IN THE MANUFACTURE OF USEFUL COMPOSITIONS IN THE TREATMENT OF CEREBELAR ATAXY. |
| PCT/EP1998/008532 WO1999033481A2 (en) | 1997-12-26 | 1998-12-22 | Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia |
| EP98966697A EP1039924A2 (en) | 1997-12-26 | 1998-12-22 | Process using the growth factor igf-1 in the manufacture of compositions that are useful in the treatment of cerebellar ataxia |
| AU24182/99A AU2418299A (en) | 1997-12-26 | 1998-12-22 | Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia |
| ARP980106700 AR014196A1 (en) | 1997-12-26 | 1998-12-28 | USE OF THE IGF-I GROWTH FACTOR IN THE MANUFACTURE OF USEFUL COMPOSITIONS IN THE TREATMENT OF CEREBELAR ATAXY |
| ZA9811896A ZA9811896B (en) | 1997-12-26 | 1998-12-28 | Process using the growth factor IGF-I in the manufacture of compositions that are useful in the treatment of cerebellar ataxia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES9702702A ES2146530B1 (en) | 1997-12-26 | 1997-12-26 | USE OF THE IGF-I GROWTH FACTOR IN THE MANUFACTURE OF USEFUL COMPOSITIONS IN THE TREATMENT OF CEREBELAR ATAXY. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2146530A1 ES2146530A1 (en) | 2000-08-01 |
| ES2146530B1 true ES2146530B1 (en) | 2001-04-16 |
Family
ID=8301638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES9702702A Expired - Fee Related ES2146530B1 (en) | 1997-12-26 | 1997-12-26 | USE OF THE IGF-I GROWTH FACTOR IN THE MANUFACTURE OF USEFUL COMPOSITIONS IN THE TREATMENT OF CEREBELAR ATAXY. |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1039924A2 (en) |
| AR (1) | AR014196A1 (en) |
| AU (1) | AU2418299A (en) |
| ES (1) | ES2146530B1 (en) |
| WO (1) | WO1999033481A2 (en) |
| ZA (1) | ZA9811896B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000013650A2 (en) * | 1998-09-03 | 2000-03-16 | Neuronz Limited | Neuroprotection |
| ES2207387B1 (en) * | 2002-02-28 | 2005-07-16 | Consejo Sup. Investig. Cientificas | CHEMICAL COMPOSITION OF IGF-I FOR THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4747825A (en) * | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5492891A (en) * | 1991-09-05 | 1996-02-20 | Novo Nordisk A/S | Method for treatment of patients with chronic liver disease |
| HU217543B (en) * | 1992-06-12 | 2000-02-28 | Albert Einstein College Of Medicine Of Yeshiva University | Process for producing pharmaceutical compositions prevention and treatment of peripherial neuropathy and pharmaceutical compositions containing insulin-like growth factor i and chemotherapeutic agent |
-
1997
- 1997-12-26 ES ES9702702A patent/ES2146530B1/en not_active Expired - Fee Related
-
1998
- 1998-12-22 AU AU24182/99A patent/AU2418299A/en not_active Abandoned
- 1998-12-22 WO PCT/EP1998/008532 patent/WO1999033481A2/en not_active Application Discontinuation
- 1998-12-22 EP EP98966697A patent/EP1039924A2/en not_active Withdrawn
- 1998-12-28 ZA ZA9811896A patent/ZA9811896B/en unknown
- 1998-12-28 AR ARP980106700 patent/AR014196A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2146530A1 (en) | 2000-08-01 |
| WO1999033481A2 (en) | 1999-07-08 |
| WO1999033481A3 (en) | 1999-09-10 |
| ZA9811896B (en) | 1999-06-28 |
| AR014196A1 (en) | 2001-02-07 |
| AU2418299A (en) | 1999-07-19 |
| EP1039924A2 (en) | 2000-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036448A1 (en) | PHARMACEUTICAL COMPOSITIONS OF INSULIN-OLIGOMER DRUGS AND METHODS TO TREAT DISEASES WITH THEMSELVES | |
| ES2133413T3 (en) | INJECTABLE LECITHIN GEL. | |
| ES2179351T3 (en) | AMIDAS ACIDAS OF PIRIDIL ALQUENO AND PIRIDIL ALQUINO AS CYTOSTATICS AND IMMUNOSUPPRESSORS. | |
| MX161342A (en) | PROCEDURE FOR THE TREATMENT OF COLLAGENOUS TISSUE ADAPTED AS A PROSTHETIC IMPLANT | |
| MX9204861A (en) | ANALOGS OF POLYPEPTIDES THAT HAVE ACTIVITY TO RELEASE HORMONE OF GROWTH. | |
| AR024558A1 (en) | COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME | |
| ES2178779T3 (en) | NEW AMIDAS OF PIRIDIL ALCANS ACIDS AS CYTOSTATIC AGENTS AND IMMUNOSUPPRESSORS. | |
| HK1073252A1 (en) | Use of antiseptics in the manufacture of a pharmaceutical preparation for the prevention or treatment of inflammations in the interior of the human body | |
| DE68912459T2 (en) | Use of thromboxane A2 receptor antagonists for the manufacture of a pharmaceutical composition for the treatment of skin diseases. | |
| ES2033667T3 (en) | PHARMACEUTICAL COMPOSITION CONTAINING FRACTIONS OF TIMO EXTRACTS. | |
| ATE187642T1 (en) | USE OF NORASTEMIZOLE FOR THE TREATMENT OF ALLERGIC RHINITIS | |
| SE503436C2 (en) | Pyroglutamidderivat | |
| DE68924006D1 (en) | Pharmaceutical compositions with eggshell components and their preparation and use. | |
| ES2146530B1 (en) | USE OF THE IGF-I GROWTH FACTOR IN THE MANUFACTURE OF USEFUL COMPOSITIONS IN THE TREATMENT OF CEREBELAR ATAXY. | |
| UY27827A1 (en) | COMPOSITIONS AND THERAPEUTIC USE | |
| ES2177849T3 (en) | PHARMACEUTICAL PREPARATION, CONTAINING 2-PHENYL-1,2-BENZOISOSELENAZOL-3 (2H) -ONA, FOR THE TREATMENT OF ALZHEIMER'S DISEASE. | |
| ES2159357T3 (en) | TERPENOID DERIVATIVES (SARCODICTINES) USEFUL AS ANTITUMOR AGENTS. | |
| ES2191189T3 (en) | PROCEDURE AND COMPOSITION FOR ANTIPARASITARY TREATMENT OF ANIMAL ENVIRONMENT. | |
| DE60321554D1 (en) | NEW ANALOGUE OF NITROBENZYL THIOINOSINE | |
| YU146490A (en) | S-SUBSTITUTED BETA-THIOACRYLAMIDES AND THEIR USE AS MICROBICIDES | |
| ES2168772T3 (en) | USE OF HORMONE OF GROWTH IN COMPOSITIONS FOR THE TREATMENT OF HEART RESISTANCE TO INSULIN. | |
| ATE110277T1 (en) | USE OF GNRH ANALOG IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF MOTILITY DISORDERS. | |
| DE68902212T2 (en) | IMMUNOTOXINS FOR TREATMENT OR PROPHYLAXIS OF AUTOIMMUNE DISEASES. | |
| ATE130194T1 (en) | SUBCUTANEOUS ADMINISTRATION OF HUMAN CHORIONIC GONADOTROPINE. | |
| ES2018807B3 (en) | PROCEDURE TO TREAT LEATHER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20000801 Kind code of ref document: A1 Effective date: 20000801 |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20110819 |